Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Impact of Freezing Delay Time on Tissue Samples for Metabolomic Studies.

Haukaas TH, Moestue SA, Vettukattil R, Sitter B, Lamichhane S, Segura R, Giskeødegård GF, Bathen TF.

Front Oncol. 2016 Jan 28;6:17. doi: 10.3389/fonc.2016.00017. eCollection 2016.

2.

High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T.

Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17.

3.

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS.

Breast Cancer Res. 2014 Jan 21;16(1):R5. doi: 10.1186/bcr3597.

4.

Metabolic changes in psoriatic skin under topical corticosteroid treatment.

Sitter B, Johnsson MK, Halgunset J, Bathen TF.

BMC Dermatol. 2013 Aug 14;13:8. doi: 10.1186/1471-5945-13-8.

5.

Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery.

Bathen TF, Geurts B, Sitter B, Fjøsne HE, Lundgren S, Buydens LM, Gribbestad IS, Postma G, Giskeødegård GF.

PLoS One. 2013 Apr 17;8(4):e61578. doi: 10.1371/journal.pone.0061578. Print 2013.

6.

Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers.

Giskeødegård GF, Lundgren S, Sitter B, Fjøsne HE, Postma G, Buydens LM, Gribbestad IS, Bathen TF.

NMR Biomed. 2012 Nov;25(11):1271-9. doi: 10.1002/nbm.2798. Epub 2012 Mar 8.

PMID:
22407957
7.

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.

Cao MD, Giskeødegård GF, Bathen TF, Sitter B, Bofin A, Lønning PE, Lundgren S, Gribbestad IS.

BMC Cancer. 2012 Jan 25;12:39. doi: 10.1186/1471-2407-12-39.

8.

In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.

Bathen TF, Heldahl MG, Sitter B, Vettukattil R, Bofin A, Lundgren S, Gribbestad IS.

MAGMA. 2011 Dec;24(6):347-57. doi: 10.1007/s10334-011-0280-9. Epub 2011 Sep 10.

PMID:
21909791
9.

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.

Cao MD, Sitter B, Bathen TF, Bofin A, Lønning PE, Lundgren S, Gribbestad IS.

NMR Biomed. 2012 Feb;25(2):369-78. doi: 10.1002/nbm.1762. Epub 2011 Aug 8.

PMID:
21823183
10.

Alignment of high resolution magic angle spinning magnetic resonance spectra using warping methods.

Giskeødegård GF, Bloemberg TG, Postma G, Sitter B, Tessem MB, Gribbestad IS, Bathen TF, Buydens LM.

Anal Chim Acta. 2010 Dec 17;683(1):1-11. doi: 10.1016/j.aca.2010.09.026. Epub 2010 Sep 24.

PMID:
21094376
11.

Merging transcriptomics and metabolomics--advances in breast cancer profiling.

Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL, Gribbestad IS.

BMC Cancer. 2010 Nov 16;10:628. doi: 10.1186/1471-2407-10-628.

12.

HR MAS MR spectroscopy in metabolic characterization of cancer.

Moestue S, Sitter B, Bathen TF, Tessem MB, Gribbestad IS.

Curr Top Med Chem. 2011;11(1):2-26. Review.

PMID:
20809888
13.

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.

Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS.

BMC Cancer. 2010 Aug 17;10:433. doi: 10.1186/1471-2407-10-433.

14.

Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation.

Bathen TF, Sitter B, Sjøbakk TE, Tessem MB, Gribbestad IS.

Cancer Res. 2010 Sep 1;70(17):6692-6. doi: 10.1158/0008-5472.CAN-10-0437. Epub 2010 Aug 10. Review.

15.

Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.

Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS.

NMR Biomed. 2010 May;23(4):424-31. doi: 10.1002/nbm.1478. Epub 2010 Jan 25.

PMID:
20101607
16.

Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.

Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF.

J Proteome Res. 2010 Feb 5;9(2):972-9. doi: 10.1021/pr9008783.

PMID:
19994911
17.

Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy.

Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF.

Mol Cancer. 2008 Apr 25;7:33. doi: 10.1186/1476-4598-7-33.

18.

Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas.

Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS.

BMC Cancer. 2007 Jan 17;7:11.

19.

MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

Bathen TF, Jensen LR, Sitter B, Fjösne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S.

Breast Cancer Res Treat. 2007 Aug;104(2):181-9. Epub 2006 Oct 24.

PMID:
17061040
20.

Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.

Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS.

NMR Biomed. 2006 Feb;19(1):30-40.

PMID:
16229059

Supplemental Content

Loading ...
Support Center